Last reviewed · How we verify
Enarodustat 2mg
Enarodustat 2mg is a Small molecule drug developed by Shenzhen Salubris Pharmaceuticals Co., Ltd.. It is currently FDA-approved.
Enarodustat 2mg, marketed by Shenzhen Salubris Pharmaceuticals Co., Ltd., is a drug with a key composition patent expiring in 2028. Its primary strength lies in its current market position, leveraging the patent protection to maintain exclusivity. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics.
At a glance
| Generic name | Enarodustat 2mg |
|---|---|
| Sponsor | Shenzhen Salubris Pharmaceuticals Co., Ltd. |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Enarodustat 2mg CI brief — competitive landscape report
- Enarodustat 2mg updates RSS · CI watch RSS
- Shenzhen Salubris Pharmaceuticals Co., Ltd. portfolio CI
Frequently asked questions about Enarodustat 2mg
What is Enarodustat 2mg?
Who makes Enarodustat 2mg?
What development phase is Enarodustat 2mg in?
Related
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing